Expansion into BFS Manufacturing Nephron Pharmaceuticals recently announced a $10 million investment in Blow-Fill-Seal (BFS) manufacturing capacity. This presents an opportunity to explore partnerships with companies in need of BFS solutions for pharmaceutical packaging.
Specialty Syringe Manufacturing Facility Investment With a $400 million investment in the InjectEZ specialty syringe manufacturing facility, Nephron Pharmaceuticals is enhancing its capabilities in syringe production. This positions the company to target clients looking for innovative syringe solutions.
Strategic Partnerships for Modern Formulations The partnership with NRx Pharmaceuticals to create tamper-resistant ketamine formulations indicates a focus on modern drug delivery solutions. This collaboration opens doors for Nephron Pharmaceuticals to engage with organizations seeking advanced drug delivery technologies.
Major Financial Investments from PNC and BlackRock Nephron Pharmaceuticals received a total of $700 million investment from PNC Financial Services Group and BlackRock Capital Investment Advisors. This financial backing can provide stability and confidence for potential clients considering partnerships or purchases.
High-Level Executive Appointments Appointing Morgan Nichols Scarnecchia as Chief of Staff and Julie Rameas as Chief Procurement Officer signifies a focus on strategic leadership and procurement functions. Leveraging these key personnel can be advantageous for engaging with companies looking for strong leadership and procurement expertise.
28K
$1B
49K$1B
87K$1B
103K$1B
60K$1B
102K$1B
73K$1B
54K$1B
78K$1B
92K$1B
36K$1B
46K$1BNephron Pharmaceuticals uses 8 technology products and services including TrackWise Digital, Cart Functionality, Exhibit, and more. Explore Nephron Pharmaceuticals's tech stack below.
| Nephron Pharmaceuticals Email Formats | Percentage |
| FLast@nephronpharm.com | 99% |
| First.Last@nephronpharm.com | 1% |
Pharmaceutical ManufacturingSouth Carolina, United States501-1000 Employees
Nephron Pharmaceuticals Corporation is a mid-sized company that manufactures generic respiratory medications. NPC sells to many classes of trade, including, but not limited to, hospitals, pharmacies, long term care facilities, home care companies and mail order pharmacies. These medications are used in the treatment of asthma and COPD.
Company Overview
Media & News
Funding & FinancialsNephron Pharmaceuticals's revenue is in the range of $100M$1B
Funding & FinancialsNephron Pharmaceuticals's revenue is in the range of $100M$1B
1-888-653-2347 
support@leadiq.com